Navigation Links
PAREXEL International To Present At Citi Global Healthcare Conference
Date:2/20/2013

BOSTON, Feb. 20, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Citi Global Healthcare Conference in New York.  James Winschel, Sr. Vice President and Chief Financial Officer, will be making a presentation on PAREXEL and discussing business developments at 10:20 a.m.  ET on Wednesday, February 27, 2013.

A live webcast of the presentation will be available through the "Investors" section of PAREXEL's website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until May 27, 2013.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 74 locations throughout 51 countries around the world, and has approximately 14,000 employees, including 282 employees related to the acquisition of Liquent. For more information about PAREXEL International visit '/>"/>

SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PAREXEL International Reports Second Quarter Fiscal Year 2013 Results
2. PAREXEL International To Present At Oppenheimer Healthcare Conference
3. PAREXEL International To Present At Lazard Capital Healthcare Conference And Jefferies Global Healthcare Conference
4. PAREXEL and Salem State University Launch Clinical Trial Management Graduate Program
5. PAREXEL International to Present at Robert Baird Healthcare Conference
6. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
7. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
8. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
9. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
10. PAREXEL International To Present At NASDAQ OMX Investor Conference
11. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 National Community Pharmacists Association (NCPA) ... the following statement in response to a new ... documenting that a number of generic drug costs increased ... with concerns previously expressed by NCPA and underscores the ... to essential medications. Moreover, a 2015 survey of 700 ...
(Date:5/28/2015)... , May 27, 2015 The amount ... billion in 2014 and with growth of 8% will ... categories out of pocket: directly on expenditures, co-pays as ... purchases, and on premiums.  The publisher made its finding ... in the United States . ...
(Date:5/28/2015)...  The U.S. Department of Justice (DOJ) has entered ... Medical Inc. to resolve a lawsuit that began more ... whistleblower lawsuit by two former employees of Orbit.  The ... of one of Orbit,s top executives, Jake Kilgore ... payment from Medicare for electric wheelchairs.  The lawsuit was ...
Breaking Medicine Technology:NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4
... and FOSTER CITY, Calif., Dec. 11 /PRNewswire-FirstCall/,-- ... and Gilead Sciences, Inc.,(Nasdaq: GILD ) ... 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300,mg) ... suppressed adults with,HIV-1 infection, subject to the ...
... Three-fold Lower Incidence of Severe Cardiac Toxicity With Equivalent ... ... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) announced today ... CPOP-R to CHOP-R in the,first-line treatment of patients with ...
Cached Medicine Technology:Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
(Date:5/28/2015)... 28, 2015 The Clinical Data ... that the International Organization for Standardization (ISO) now ... (BRIDG) Model version 3.2 as a published, Final ... with healthcare. This standard, which had previously passed ... was unanimously approved on 24 April for publication ...
(Date:5/28/2015)... 28, 2015 Park Cities Pet Sitter is ... Training class starting Saturday, June 6th at 10:30am. ... 5831 McCommas Blvd in Dallas, with a maximum of six ... for five weeks, with no class being held over the ... $135. , In this Intermediate-to-Advanced level class, dogs will solidify ...
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... opening a new location for his Shore Vascular & Vein ... treatment of the circulatory system. It is his mission ... compassion, consideration and respect. , Dr. Jeffrey Gosin ... a graduate of the University of Pennsylvania and Jefferson Medical ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... 2015 Medelis, Inc., a specialty oncology ... company in the role of president. , “ Bill Taaffe ... CRO industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He ... our next phase of growth.” , Taaffe joined ICON’s ... nine employees to over 4,500 employees, achieving 12 consecutive years ...
Breaking Medicine News(10 mins):Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 2Health News:CDISC Announces BRIDG Model for Research as Final ISO Standard 3Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... plays a major role in kidney failure, and blocking the ... disease in diabetes, according to researchers. "We believe these ... can slow down the progression of, or even prevent the ... professor of nephrology, Penn State College of Medicine. In the ...
... News) -- Low vitamin D levels are common among spine ... says. Vitamin D helps with calcium absorption. Spine surgery ... producing new bone, explained researchers at Washington University School of ... spinal fusion surgery and found that more than half of ...
... , FRIDAY, Nov. 4 (HealthDay News) -- "Leatherhead" football ... modern helmets, a new study reports, but no one is ... researchers said their findings point to the need for improvements ... research team conducted lab tests to compare head injury risks ...
... crystallography, researchers Xiaohu Mei, PhD, and David Atkinson, PhD, from ... time obtained an "image" of the structure and the precise ... apolipoprotein A-I (apoA-I) molecule. The findings, which appear in the ... may lead to the development of new drugs to treat ...
... a new study being published early online in Annals ... College of Physicians, birth cohort screening for hepatitis C is ... strategy could identify over 800,000 currently unidentified cases, which could ... percent of the nation,s population is infected with hepatitis C ...
... A gene variation associated with an increased risk of autism ... three to four times more likely than girls to be ... genomic data from more than 3,000 children with autism and ... The results showed a link between a variation in the ...
Cached Medicine News:Health News:Research aims to prevent diabetic kidney failure 2Health News:Vitamin D Lacking in Many Spine Surgery Patients 2Health News:Newer Not Necessarily Better for Football Helmet Design 2Health News:Researchers identify structure of apolipoprotein 2Health News:Birth cohort screening for hepatitis C is cost effective, could save thousands of lives each year 2Health News:Possible Genetic Link to Autism Identified 2
An economical solution to the need to provide wrap-around protection. The one-sided velcro closure allows greater flexibility in sizing. Front protection is 0.5mm Pb and the back is 0.25mm Pb equival...
This wrap around apron features a uniquely designed orthopedic wide belt that is integrated directly on the apron....
The most comfortable and easy to use apron in the industry. This front protection apron comes with a fully adjustable snap-on 5" orthopedic belt to relieve weight off your shoulders. Velcro strap acr...
Unique criss-cross strapping. The MSV-10 is our most popular model. Extra wide Velcro ensures a wide variety of adjustments and easy closing....
Medicine Products: